|
Date
|
Article
|
08-02-2005
|
Shire Laboratories receives US Patent #6,913,768 for Sustained Release Delivery of Amphetamine Salts.
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent #6,913,768 for Sustained release delivery of amphetamine salts.
|
08-01-2005
|
CollaGenex Pharmaceuticals Files New Drug Application for Oracea.
CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI), a Shire Laboratories Partner, today announced it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Oracea(TM), the first orally administered, systemically delivered drug to treat rosacea.
|
05-10-2005
|
Shire Laboratories receives US Patent # 6,890,918 for Pharmaceutical Compositions Including ACE/NEP Inhibitors and Bioavailability Enhancers.
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,890,918 for the company's pharmaceutical composition which has improved systemic bioavailability.
|
01-04-2005
|
Shire Laboratories receives US Patent # 6,838,093 on a System for Osmotic Delivery of Pharmaceutically Active Agents
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,838,093 for the company's system for osmotic delivery of pharmaceutically active agents.
|
11-30-2004
|
Osmotic Drug Delivery Systems for Poorly Soluble Drugs
Read this Article by Padmanabh P. Bhatt, Ph.D., Vice President, Advanced Drug Delivery, Published in The Drug Delivery Companies Report, Autumn/Winter 2004.
|
11-09-2004
|
Shire Laboratories receives US Patent # 6,814,979 on Osmotic Drug Delivery System
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,814,979 on the company's Osmotic Drug Delivery System.
|
11-02-2004
|
Shire Laboratories receives US Patent # 6,811,794 Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,811,794 on the company's Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles.
|
10-13-2004
|
Shire Laboratories receives US Patent # 6,793,934 on Solid Oral Dosage Form
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,793,934 on the company's Solid Oral Dosage Form.
|
08-12-2004
|
US Food & Drug Administration (FDA) Approves Adderall XR(R) To Treat Adults
Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX:SHQ) announces that its leading treatment for Attention Deficit Hyperactivity Disorder (ADHD), ADDERALL XR® (mixed salts of a single-entity amphetamine) has been approved by the US FDA as a once-daily treatment for adults.
|
06-15-2004
|
CollaGenex Pharmaceuticals Initiates Two Phase 3 Clinical Trials to Evaluate Col-101 for the Treatment of Rosacea
CollaGenex Pharmaceuticals, Inc. (Nasdaq:CGPI) today announced that the FDA has cleared the way for the immediate enrollment of patients in two Phase 3 clinical trials of Col-101, the Company's once daily, modified-release formulation of doxycycline, 40 mg, for the treatment of rosacea.
|
04-07-2004
|
PLIVA Signs Deal for Exclusive US Rights to SANCTURA (TM)
PLIVA d.d. ("PLIVA") announced today a significant step in the strategic expansion of its US proprietary business through the signing of an exclusive license and commercialisation agreement between its specialty branded subsidiary, Odyssey Pharmaceuticals, Inc., and Indevus Pharmaceuticals, Inc. for the co-promotion of SANCTURA (TM) (trospium chloride) in the US.
|
03-24-2004
|
QRxPharma and Shire Laboratories Collaborate on a Novel Controlled Release Opioid Product
Immediate Release Formulation of Novel Opioid is Ready to Enter Phase III Clinical Trials in 2004
|
10-20-2003
|
Approvable Letter for Adult Adderall XRŽ, From US FDA
Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that it has received an 'approvable' letter from the US FDA for ADDERALL XRŽ once daily treatment for adult Attention Deficit Hyperactivity Disorder (ADHD)
|
08-12-2003
|
Shire Pharmaceuticals Group plc receives US Patent #6,605,300
Shire Pharmaceuticals Group plc (Nasdaq: SHPGY; LSE: SHP.L,) announced today that the US Patent and Trademark Office has issued US Patent # 6,605,300 for the company's multiple pulsed dose drug delivery system.
|
07-25-2003
|
Shire Laboratories Partnership:
CollaGenex Pharmaceuticals Reports Progress with Development of Sustained Release Once-Daily Periostat® Formulation
|
03-11-2003
|
Indevus and Shire to Collaborate on Extended Release Trospium Development Program
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced that it has signed an exclusive agreement with Shire Laboratories Inc., a subsidiary of Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ).
|
02-06-2003
|
Padmanabh (Pad) Bhatt, Ph.D. has joined Shire Laboratories Inc ( SLI )
Padmanabh (Pad) Bhatt, Ph.D. has joined Shire LaboratoriesInc ( SLI ) as Vice President of Advanced Drug Delivery.
|
05-23-2002
|
ADDERALL XR™ - FDA Approves Three New Strengths
Shire Pharmaceuticals Group plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) announces that it has received Food and Drug Administration (FDA) approval for three further strengths of ADDERALL XR(TM) (mixed salts of a single entity amphetamine product), its once a day treatment for Attention Deficit Hyperactivity Disorder (ADHD).
|
05-07-2002
|
Shire Laboratories receives US Patent # 6,384,020 on rapid immediate release oral dosage form
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,384,020 for the company's rapid immediate release oral dosage form.
|
03-26-2002
|
Shire Laboratories receives US Patent # 6,361,796 on soluble form osmotic dose delivery system
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,361,796 for the company's soluble form osmotic dose delivery system.
|
11-27-2001
|
Shire Laboratories receives US Patent # 6,322,819 on oral pulsed dose drug delivery system
Shire Laboratories, Inc. announced today that the US Patent and Trademark Office has issued US Patent # 6,322,819 for the company's oral pulsed dose drug delivery system.
|
10-12-2001
|
FDA Approves ADDERALL XR™ For Once-Daily Treatment of Attention Deficit/Hyperactivity Disorder
Shire Pharmaceuticals Group plc (Nasdaq: SHPGY; LSE: SHP.L,) announced today that the U.S. Food and Drug Administration approved ADDERALL XR™ for the treatment of attention deficit/hyperactivity disorder (ADHD).
|
09-11-2001
|
Shire Laboratories Receives US Patent # 6,287,599 on Matrix Drug Delivery Technology, Solutrol®
Shire Laboratories Inc. today announced that the U.S. Patent and Trademark Office has issued US Patent # 6,287,599 for the company's novel matrix drug delivery technology, Solutrol®.
|
09-04-2001
|
Shire Laboratories Receives US Patent # 6,284,276 on its Osmotic Drug Delivery Technology, EnSoTrol®
Shire Laboratories Inc. today announced that the U.S. Patent and Trademark Office has issued US Patent # 6,284,276 for the company's novel osmotic drug delivery technology, EnSoTrol®.
|
07-11-2001
|
Shire Laboratories Receives Notice of Allowance on Matrix Drug Delivery Technology, Solutrol®.
Shire Laboratories Inc. today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the company's patent application related to its novel matrix drug delivery technology, Solutrol®.
|
07-03-2001
|
Shire Laboratories Receives Third Notice of Allowance on Osmotic Drug Delivery Technology, EnSoTrol®.
Shire Laboratories Inc. today announced that the U.S. Patent and Trademark Office has issued a third Notice of Allowance for the company's patent application related to its novel osmotic drug delivery technology, EnSoTrol®.
|
06-11-2001
|
Shire Laboratories Inc And Ricerca, LLC Announce Strategic Alliance
Ricerca's drug lead optimization, candidate selection programs and preclinical drug development expertise compliments Shire's platforms for predicting and enhancing oral bioavailability and for developing unique oral controlled release formulations.
|
05-11-2001
|
Shire Laboratories Receives Second Notice of Allowance on Osmotic Drug Delivery Technology, EnSoTrol®
Shire Laboratories Receives Second Notice of Allowance on Osmotic Drug Delivery Technology, EnSoTrol®.
|
01-18-2001
|
Confirmation of In Vitro/In vivo Predictability
In vitro/in vivo predictability of ProScreen/OptiScreen platform has been confirmed via comparison of pharmacokinetic and cell line transport data for three commercial products.
|
12-18-2000
|
Shire Announces Promising Data on Sampatrilat
Shire Pharmaceuticals Group plc announces promising results from the reformulation of sampatrilat, a dual inhibitor of neutral endopeptidase and angiotension converting enzyme.
|
11-29-2000
|
Shire Laboratories Announces The Signing of Four Partnerships.
Shire Laboratories Inc., a subsidiary of the Shire Pharmaceuticals Group plc ("Shire") (LSE: SHP.L, NASDAQ: SHPGY), today announced that it signed four partnerships with different pharmaceutical companies in the year 2000.
|
10-04-2000
|
Once-a-Day ADDERALLŽ for ADHD submitted to FDA.
Shire Pharmaceuticals Group plc (LSE : SHP.L, Nasdaq : SHPGY) announces that a New Drug Application for SLI 381, the novel once-a-day formulation of Adderall for Attention Deficit Hyperactivity Disorder (ADHD) was delivered to the FDA yesterday.
|
08-29-2000
|
Shire Laboratories Receives US Patent for Novel Osmotic Drug Delivery Technology, EnSoTrol (R).
Shire Laboratories Receives US Patent for Novel Osmotic Drug Delivery Technology, EnSoTrol (R).
|
04-28-2000
|
Shire Laboratories Receives Notice Of Allowance On Osmotic Drug Delivery Technology, EnSoTrolŽ
Shire Laboratories Inc. today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the company's patent application related to its novel osmotic drug delivery technology, EnSoTrol®.
|
